Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Expression of B7-H1, a costimulating glycoprotein in the B7 family, is normally restricted to macrophage-lineage cells, providing a potential costimulatory signal source for regulation of T cell activation. In contrast, aberrant expression of B7-H1 by tumor cells has been implicated in impairment of T cell function and survival, resulting in defective host antitumoral immunity. The relationship between tumor-associated B7-H1 and clinical cancer progression is unknown. Herein, we report B7-H1 expression by both renal cell carcinoma (RCC) tumors of the kidney and RCC tumor-infiltrating lymphocytes. In addition, our analysis of 196 clinical specimens reveals that patients harboring high intratumoral expression levels of B7-H1, contributed by tumor cells alone, lymphocytes alone, or tumor and/or lymphocytes combined, exhibit aggressive tumors and are at markedly increased risk of death from RCC. In fact, patients with high tumor and/or lymphocyte B7-H1 levels are 4.5 times more likely to die from their cancer than patients exhibiting low levels of B7-H1 expression (risk ratio 4.53; 95% confidence interval 1.94–10.56; P < 0.001.) Thus, our study suggests a previously undescribed mechanism whereby RCC may impair host immunity to foster tumor progression. B7-H1 may prove useful as a prognostic variable for RCC patients both pre- and posttreatment. In addition, B7-H1 may represent a promising target to facilitate more favorable responses in patients who require immunotherapy for treatment of advanced RCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Subsequent human studies have consistently shown that PD-L1 and PD-L2 expression not only increases in cancerous tissues but is also linked to poor disease prognosis in many cancer types (50)(51)(52)(53)(54)(55)(56).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [50]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Self-citationIwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Self-citationPhan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
The Heidelberg classification of renal cell tumours
Kovacs, G., Akhtar, M., Beckwith, B. J., Bugert, P., Cooper, C. S., Delahunt, B., Eble, J. N., Fleming, S., Ljungberg, B., Medeiros, L. J., et al. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199710)183:2<131::aid-path931>3.0.co;2-g · Cited by 1,354
FRANK, I., BLUTE, M. L., CHEVILLE, J. C., LOHSE, C. M., WEAVER, A. L., & ZINCKE, H. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64153-5 · Cited by 1,175
Self-citationComparisons of Outcome and Prognostic Features Among Histologic Subtypes of Renal Cell Carcinoma
Cheville, J. C., Lohse, C. M., Zincke, H., Weaver, A. L., & Blute, M. L. (2003) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200305000-00005 · Cited by 1,087
Self-citationHodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006
CTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940
THE CHANGING NATURAL HISTORY OF RENAL CELL CARCINOMA
PANTUCK, A. J., ZISMAN, A., & BELLDEGRUN, A. S. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)65640-6 · Cited by 882
Research works printed but not linked: 13
- Strome, S.-E., Dong, H., Tamura, H., Voss, S.-G., Flies, D.-B., Tamada, K., Salomao, D., Cheville, J.-C, Hirano, F., Lin, W., et al. (2003) Cancer Res. 63, 6501–6505. [PubMed] [Google Scholar]
- Graham, S., Babayan, R.-K., Lamm, D.-L., Sawczuk, I., Ross, S.-D., Lavin, P.-T., Osband, M.-E. & Krane, R.-J. (1993) Semin. Urol. 11, 27–34. [PubMed] [Google Scholar]
- Krejci, K.-G., Markiewicz, M.-A. & Kwon, E.-D. (2003) J. Urol. 171, 870–876. [DOI] [PubMed] [Google Scholar]
- Nakano, O., Sato, M., Naito, Y., Suzuki, K., Orikasa, S., Aizawa, M., Suzuki, Y., Shintaku, I., Nagura, H. & Ohtani, H. (2001) Cancer Res. 61, 5132–5136. [PubMed] [Google Scholar]
- Storkel, S., Eble, J.-N., Adlakha, K., Amin, M., Blute, M.-L., Bostwick, D.-G., Darson, M., Delahunt, B. & Iczkowski, K. (1997) Cancer 80, 987–989. [DOI] [PubMed] [Google Scholar]
- Wintterle, S., Schreiner, B., Mitsdoerffer, M., Schneider, D., Chen, L., Meyermann, R., Weller, M. & Wiendl, H. (2003) Cancer Res. 63, 7462–7467. [PubMed] [Google Scholar]
- Uzzo, R.-G., Rayman, P., Kolenko, V., Clark, P.-E., Bloom, T., Ward, A.-M., Molto, L., Tannenbaum, C., Worford, L.-J, Bukowski, R.-M., et al. (1999) Clin. Cancer Res. 5, 1219–1229. [PubMed] [Google Scholar]
- Alexander, J.-P., Kudoh, S., Melsop, K.-A., Hamilton, T.-A., Edinger, M.-G., Tubbs, R.-R., Sica, D., Tuason, L., Klein, E., Bukowski, R., et al. (1993) Cancer. Res. 53, 1380–1387. [PubMed] [Google Scholar]
- Li, X., Liu, J., Park, J.-K., Hamilton, T.-A., Rayman, P., Klein, E., Edinger, M., Tubbs, R., Bukowski, R. & Finke, J. (1994) Cancer Res. 54, 5424–5429. [PubMed] [Google Scholar]
- Kudoh, S., Redovan, C., Rayman, P., Edinger, M., Tubbs, R.-R., Novick, A., Finke, J.-H. & Bukowski, R.-M. (1997) J. Immunol. 20, 479–487. [DOI] [PubMed] [Google Scholar]
- Motzer, R.-J. (2003) Crit. Rev. Oncol. Hematol. 46S, s33–s39. [DOI] [PubMed] [Google Scholar]
- Hofmockel, G., Tsatalpas, P., Muller, H., Dammrich, J., Poot, M., Maurer-Schultze, B., Muller-Hermelink, H.-K., Frohmuller, H.-G. & Bassukas, I.-D. (1995) Cancer 76, 296–306. [DOI] [PubMed] [Google Scholar]
- Shimazui, T., Oosterwijk, E., Akaza, H., Bringuier, P., Ruijter, E., van Berkel, H., Wakka, J.-O., van Bokhoven, A., Debruyne, F.-M. & Schalken, J.-A. (1998) Clin. Cancer Res. 4, 2419–2424. [PubMed] [Google Scholar]
Cited by
Items 701–796 of 796
Promising Immunotherapeutic Approaches in Clinical Trials
Rotte, A., & Bhandaru, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-48066-4_15 · Cited by 1
Cancer Immunotherapy Arsenal: Current and Promising New Approaches
Koppolu, V. (2017) · Cancer therapy & Oncology International Journal · doi:10.19080/ctoij.2017.05.555661 · Cited by 1
Targeting the Pd-1 Pathway in Renal Cell Carcinoma: A Review
Derosa, L., Albiges, L. K., & Escudier, B. J. (2017) · Journal of Onco-Nephrology · doi:10.5301/jo-n.5000027 · Cited by 1
Yu, W., Chen, L., Guo, S., Luo, L., & Chen, L. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1504156 · Cited by 1
Self-citationRegulation of PD-L1 Expression by Histone Deacetylase Inhibitor SAHA in Lung Cancer Cells
Rathinavelu, A. (2019) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2019.19.003348 · Cited by 1
Duijvesz, D., & Jenster, G. W. (2012) · Springer eBooks · doi:10.1007/978-1-4471-2864-9_35 · Cited by 1
Pardoll, D. M. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50009-9 · Cited by 1
PD-L1 and the Clinical Outcomes of Ovarian Cancer: Meta-Analysis and Bioinformatical Analysis
Shi, X., Liu, Y., Liu, L. C., Ding, H., Liang, D., Geng, F., Yu, H., Ban, J., Li, J., Gui, W., et al. (2022) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2022.23.7.2285 · Cited by 1
The usage of Pembrolizumab in Metastatic Urothelial Carcinoma
Cui, W. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v36i.5700 · Cited by 1
Khan, S., Yetiskul, E., Khattar, G., Ghada, A., Afif, S., Khan, M. W. Z., & Manchandani, U. K. (2024) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2024_004619 · Cited by 1
Renal cell carcinoma and macrophage research: A bibliometric analysis (2004–2023)
Qi, D., Zhang, H., Xiong, F., Zhang, G., Tao, B., & Wang, C. (2024) · Medicine · doi:10.1097/md.0000000000040954 · Cited by 1
Babamohamadi, Z., Taherkhani, A., Yousefzadeh, A., Moradi, A., Heidari, M., Nasab, Z. S. H., Haghi, S. M., Afkhami, A., Belbasi, M., Noroozi, M., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1534343 · Cited by 1
Emerging Agents in Renal Cell Carcinoma
Pal, S. K., Josephson, D. Y., Twardowski, P. W., & Quinn, D. I. (2011) · Springer eBooks · doi:10.1007/978-3-642-21858-3_19 · Cited by 1
Harnessing iNKT cells to improve in situ vaccination for cancer therapy
Prasit, K. (2020) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17151131.v1 · Cited by 1
Modelos y algoritmos pronósticos en el carcinoma de células renales
Lane, B. R., & Kattan, M. W. (2008) · Clínicas urológicas de Norteamérica
Inman, B. A., Frigola, X., Dong, H., Yang, J. C., & Kwon, E. D. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-332-5_21
Self-citationGenetics, epigenetics and angiogenesis in renal cell carcinoma
Baldewijns, M. M. L. L. (2009) · Research Publications (Maastricht University) · doi:10.26481/dis.20090626mb
Immunomodulatory Molecules of the Immune System
Saenger, Y. M., Jenq, R. R., & Perales, M. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6087-8_5
Biomarkers for Prognosis and Molecularly Targeted Therapy in Renal Cell Carcinoma
Schmidt, L. S. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-615-9_11
Peering Through the Microscope Lens Into the Future
Tollefson, M. K., & Thompson, R. H. (2010) · European Urology · doi:10.1016/j.eururo.2010.08.046
Self-citationManuel, M. (2012) · theses.fr (ABES) · doi:10.70675/832d43bfzddecz4ae7zbd79z5f13e41a9ac8
Induction Mechanism of PD-L1 (Programmed Cell Death-ligand 1) in Sepsis
Lee, S. M. (2008) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2008.65.4.343
Pharmacotherapy options for advanced renal cell carcinoma
Cerbone, L., Recine, F., & Sternberg, C. N. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.911079
Pal, S. K., Reckamp, K. L., Yu, H., & Figlin, R. A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-2400-0_11
T-cell Unresponsiveness in Renal Cell Carcinoma Patients
Finke, J. H., & Goel, M. C. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-149-3_7
Immune Checkpoint Inhibitors (Anti-CTLA4, Anti-PD-1) in RCC
Bailey, A. S., & McDermott, D. F. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1622-1_21
Beck, T. N., Golemis, E. A., & Geynisman, D. M. (2016) · European Urology · doi:10.1016/j.eururo.2016.02.048
Immune Checkpoint Inhibition in Renal Cell Carcinoma
Mahoney, K. M., Harshman, L. C., Seery, V. J., & Drake, C. G. (2015) · Springer eBooks · doi:10.1007/978-3-319-17903-2_16
Programmed death ligand -1: a review
Hemashree, J. (2017) · International Journal of Recent Scientific Research · doi:10.24327/ijrsr.2017.0803.0101
Interações entre células dendríticas, mastócitos e células tumorais.
Rodrigues, C. P. (2015) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.42.2015.tde-09062015-143842
Rossetti, S., Cecere, S. C., Pisano, C., Iovane, G., Ventriglia, J., Paciolla, I., & Napoli, M. D. (2017) · Cancer Breaking News · doi:10.19156/cbn.2017.0043
PD-1 Blockade in Renal Cell Carcinoma
Derosa, L., & Escudier, B. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_21
Anti-programmed death ligand 1 (PD-L1) inhibitors in metastatic gastric cancer
Cho, J. H., & Lee, J. (2017) · Precision and Future Medicine · doi:10.23838/pfm.2017.00177
Blockade of the Checkpoint as New Target of the Immunotherapy in the Treatment of Cancer.
Yaşin, B., & Eliyatkın, N. (2018) · The Anatolian Journal of General Medical Research · doi:10.5222/terh.2018.007
Brooks, S. A. (2015) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/zhvw-d308
Cañas, M. G. (2018) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy
Toma, A. D., Russo, G. L., Signorelli, D., Ferrara, R., Prelaj, A., Galli, G., Viscardi, G., Trevian, B., Ganzinelli, M., Zilembo, N., et al. (2020) · European Oncology & Haematology · doi:10.17925/eoh.2020.16.1.39
Issa, A. A., Yaseen, A., & Aldabagh, M. A. H. (2021) · IOP Conference Series Earth and Environmental Science · doi:10.1088/1755-1315/790/1/012065
Desbalances genómicos del locus 9p24.1 en pacientes argentinos con linfoma de Hodgkin clásico
Montenegro, M. G., Narbaitz, M., Metrebian, M. F., Pavlovsky, A., & Slavutsky, I. R. (2021) · Revista Médicas UIS · doi:10.18273/revmed.v34n1-2021004
Checkpoint Blockade and Combinatorial Immunotherapies
Peggs, K. S., Quezada, S. A., & Allison, J. P. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6087-8_16
Adjuvant Systemic Therapy, Immunotherapy, and Targeted Treatment
Cerbone, L., & Sternberg, C. N. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7236-0_20
Sharma, P., Subudhi, S. K., Peggs, K. S., Goswami, S., Gao, J., Quezada, S. A., & Allison, J. P. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm068
Emerging Agents in Renal Cell Carcinoma
Pal, S. K., Josephson, D. Y., Twardowski, P. W., & Quinn, D. I. (2015) · Springer eBooks · doi:10.1007/978-3-319-17903-2_23
Uncovering triggers of colonization in brain metastasis
Blazquez, R. (2017) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-6264
Recent pharmacological approaches for the treatment of renal cell carcinoma
Alimohammadi, A., Fajković, H., Mesut Remzi, A., Shariat, S. F., & Schmidinger, M. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2053521
Advances in the Treatment of Renal Cell Carcinoma
Reynolds, P., & Stewart, G. D. (2022) · MDPI eBooks · doi:10.3390/books978-3-0365-2934-9
Development of novel immune interventions for genito-urinary cancers
Agarwal, N., & Vogelzang, N. J. (2011) · Informa Healthcare eBooks · doi:10.3109/9781841848303.003
Higashi, K., Ogawa, T., Saiki, Y., Ishikawa, T., Kobayashi, Y., Ohkoshi, A., Nakanome, A., Katori, Y., & Horii, A. (2020) · doi:10.21203/rs.3.rs-25255/v1
Guru, S. A., Sumi, M. P., Mir, R., Waza, A. A., Bhat, M. A., Zuberi, M., Lali, P., & Saxena, A. (2020) · Human Cell · doi:10.1007/s13577-020-00394-y
Gandhi, V. V., & Bose, P. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.725372046.793538195
Zhou, X., Wu, X., Li, X., Zhang, Y., & Wang, X. (2019) · doi:10.21203/rs.2.10557/v1
Hayakawa, S. (2008) · Journal of Nihon University Medical Association · doi:10.4264/numa.67.43
Interleukin-10 Superfamily and Cancer
Yuzhalin, A. E., & Kutikhin, A. G. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-801121-8.00006-3
Checkpoint inhibition: the current treatment of renal cell carcinoma
García-Robledo, J. E., & García‐Perdomo, H. A. (2022) · Revista Mexicana de Urología · doi:10.48193/revistamexicanadeurologa.v82i2.839
Sharma, P., Anandhan, S., Siddiqui, B. A., Goswami, S., Subudhi, S. K., Gao, J., Peggs, K. S., Quezada, S. A., & Allison, J. P. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm068.pub2
Sales, N. S. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2021.tde-12082022-174356 · Cited by 1
Inceman, M., Toyran, T., Bayazit, Y., İzol, V., & Erdoğan, Ş. (2022) · Polish Journal of Pathology · doi:10.5114/pjp.2022.122613
Pravisano, F., Martina, F., Macerelli, M., Susanna, U., Pizzolitto, S., Davide, R., Claudio, V., Michela, C., Fasola, G., & Paola, E. (2023) · Annals of Medical and Clinical Oncology · doi:10.29011/2833-3497.000146
Cooper, Z. A., Juneja, V. R., Sage, P. T., Frederick, D. T., Piris, A., Mitra, D., Lo, J. A., Hodi, F. S., Freeman, G. J., Bosenberg, M., et al. (2023) · doi:10.1158/2326-6066.c.6548542.v1
Callea, M., Albiges, L. K., Gupta, M., Cheng, S., Genega, E. M., Fay, A. P., Song, J., Carvo, I., Bhatt, R. S., Atkins, M. B., et al. (2023) · doi:10.1158/2326-6066.c.6548894.v1
Dong, H., Cao, Y., Jian, Y., Lei, J., Zhou, W., Yu, X., Zhang, X., Peng, Z., & Sun, Z. (2023) · BMC Cancer · doi:10.1186/s12885-023-11408-x
Self-citationQi, W., Liu, Y., & Zhang, Q. (2024) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.spl.826
Is the epithelial-mesenchymal transition an ally or an enemy of cancer?
Sanchez Zauco Norma, A. (2023) · doi:10.52768/jjgastro/1174
Analysis of the PD-L1 Expression and Relevant Clinical Factors in Advanced Colorectal Cancer
Li, Y. (2023) · Journal of medicine and health science. · doi:10.62517/jmhs.202305401
Giatrakis, C., Kartikasari, A. E. R., Angelovich, T. A., Flanagan, K. L., Churchill, M. J., Scott, C. L., Telukutla, S. R., & Plebanski, M. (2025) · Biomolecules · doi:10.3390/biom15121685
Dong, H., Cao, Y., Jian, Y., Lei, J., Zhou, W., Yu, X., Zhang, X., Peng, Z., & Sun, Z. (2023) · Figshare · doi:10.6084/m9.figshare.24264585
Self-citationCañas, M. G. (2018) · Academica-e (Universidad Pública de Navarra)
PD-1 et BTLA au coeur des lymphocytes B : du physiologique aux lymphomes
Thibult, M. (2011) · theses.fr (ABES) · doi:10.70675/9fced0cfz093cz4a5az9efcz599aecffc537
Delfortrie, S. (2011) · theses.fr (ABES) · doi:10.70675/375353dcz58d5z4205zaa25zf6dd8ffba78f · Cited by 1
Berger, H. (2015) · theses.fr (ABES) · doi:10.70675/33cee056zccc3z4978z8945z12c4fd4adfab · Cited by 1
Integrated analysis and clinical impact of immune and stromal microenvironments in solid tumors
Petitprez, F. (2018) · theses.fr (ABES) · doi:10.70675/cea357bazafbaz4eaaz94e5zc5f644de5018
Neyrinck-Leglantier, D. (2018) · theses.fr (ABES) · doi:10.70675/fb867045zfedcz41bcza66dze69ad28d7f83
Lopresti, A. (2019) · theses.fr (ABES) · doi:10.70675/216c614ezc8f7z414cza7e4z61c22dd929c4
Boukredine, A. (2021) · theses.fr (ABES) · doi:10.70675/169b99afz5507z4d66zbbfazaaebacd91737 · Cited by 1
Savion‐Gaiger, N., Perales, O., Su, D. G., Bar‐Ziv, D., Challa, P., Djureinovic, D., Yi, I., Adeniran, A., Kluger, H. M., & Schoenfeld, D. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.106908
Mardi, A., Moghaddam, S. R., Motlagh, A. R., & Mehmandar‐Oskuie, A. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02252-x
Turan, S., Erdem, S., Hürdoğan, Ö., Özlük, Y., Ergül, R. B., Şanlı, Ö., & Özcan, F. (2026) · International Urology and Nephrology · doi:10.1007/s11255-026-05348-1
Fernández, I. P., Blanco‐Lorenzo, V., Domínguez, R. G., Gomez, C. I., Molina‐Cerrillo, J., Carbonero, I. G., Feliciangeli, E., Ruiz, S. G., de Liaño, A. G., Valderrama, B. P., et al. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04543-x
Rahman, N. Q. A., Khazali, A., Mohtar, M., & Syafruddin, S. E. (2026) · Molecular Medicine Reports · doi:10.3892/mmr.2026.14053
Bhavthankar, R., Fonseca, D., Murthy, S., Sharma, P. V., Chaudhari, P. S., & Vimal, S. S. (2026) · Indian Journal of Gynecologic Oncology · doi:10.1007/s40944-026-01184-4
OTUD1 Prevents Immunosuppression via Promoting Lysosomal‐Associated Degradation of PD‐L1
Yang, H., Zhou, H., Liu, Y., Jin, M.-J., Feng, Q., Li, T., Li, Q., Zhen, Y., Sun, T., Li, C., et al. (2026) · MedComm · doi:10.1002/mco2.71144
Overcoming Immune Suppression: Therapeutic Strategies Targeting T-Cell Function in Cancer
Weber, J. S. (2014) · Springer eBooks · doi:10.1007/978-1-4899-8056-4_16
Metadata
- Authors
- Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., Zincke, H., Blute, M. L., Strome, S. E., Leibovich, B. C., & Kwon, E. D.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2004-11-29
- Volume
- 101
- Issue
- 49
- Pages
- 17174-17179
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC534606
- OpenAlex
- W4230861071
- Cited by
- 776
- References
- 48
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 15 · 2023: 29 · 2022: 32 · 2021: 42 · 2020: 51 · 2019: 60 · 2018: 57 · 2017: 76 · 2016: 65 · 2015: 69 · 2014: 57 · 2013: 29 · 2012: 28
- FWCI
- 9.14
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-L1, renal cell carcinoma, tumor-infiltrating lymphocytes, tumor progression, prognostic factors, tumor immune evasion, T cell costimulation, immunotherapy targets, cancer mortality
- MeSH terms
- Carcinoma, Renal Cell, Follow-Up Studies, Humans, Immunity, Immunohistochemistry, Membrane Glycoproteins, Neoplasm Proteins, Peptides, Prognosis, Antigens, CD, Odds Ratio, Survival Analysis, Lymphocytes, Tumor-Infiltrating, B7-1 Antigen, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.